Phase II Clinical Trial to Evaluate the Ongoing Pregnancy Rate With OXO-001 in IVF/ICSI With Donor Oocytes.

PHASE2CompletedINTERVENTIONAL
Enrollment

408

Participants

Timeline

Start Date

September 1, 2021

Primary Completion Date

August 1, 2023

Study Completion Date

December 1, 2023

Conditions
Infertility, FemaleInfertility
Interventions
DRUG

OXO-001

OXO-001 oral administration once daily in the early morning. The treatment duration will vary depending on the woman, but it will last between 10 to 14 weeks approximately.

DRUG

Placebo

Placebo oral administration once daily in the early morning. The treatment duration will vary depending on the woman, but it will last between 10 to 14 weeks, approximately.

Trial Locations (28)

Unknown

Fertimed s.r.o., Olomouc

ISCARE centrum asistované reprodukce, Prague

IVF CUBE, Prague

Sanatorium PRONATAL, Prague

UNICA Prague s.r.o, Prague

Pronatal NORD, Teplice

Klinika reprodukční medicíny a gynekologie, Zlín

KRIOBANK Centrum Leczenia Niepłodności Ginekologia, Bialystok

ProCrea Swiss IVF Center s.r.o., Katowice

Provita Sp. z o.o., Katowice

VitroLive Sp. z o.o., Szczecin

OVIklinika, Warsaw

Przychodnia Lekarska nOvum, Katarzyna Kozioł, Piotr Lewandowski spółka jawna, Warsaw

Instituto Bernabeu, Alicante

Fertty, Barcelona

Hospital Universitari Dexeus, Barcelona

Hospital Universitario Quirónsalud Barcelona, Barcelona

IVI Barcelona, Barcelona

IVI Bilbao, Leioa

GINEFIV Madrid, Madrid

Hospital Universitario Quirónsalud Madrid, Madrid

Instituto Bernabeu Madrid, Madrid

IVI Madrid, Madrid

IVI Mallorca, Palma de Mallorca

Ginemed Sevilla, Seville

IVI Sevilla, Seville

IVI Valencia, Valencia

IVI Zaragoza, Zaragoza

Sponsors

Lead Sponsor

All Listed Sponsors
lead

OXOLIFE

INDUSTRY

NCT05076032 - Phase II Clinical Trial to Evaluate the Ongoing Pregnancy Rate With OXO-001 in IVF/ICSI With Donor Oocytes. | Biotech Hunter | Biotech Hunter